Back to Results

Indivior PLC (INDV)

Indivior PLC (NASDAQ: INDV) is a healthcare company focused on pharmaceuticals for opioid dependence and related disorders. The company develops, manufactures, and sells buprenorphine-based prescription medicines in the United States, Europe, Canada, Australia, and other international markets. Its marketed products include SUBLOCADE, a monthly extended-release injection, and SUBOXONE Film, a buprenorphine and naloxone sublingual film. Indivior also produces SUBOXONE Tablet and SUBUTEX Tablet for opioid use disorder. Beyond its commercial portfolio, the company is advancing INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 testing for moderate to severe OUD, and INDV-6001, a long-acting injectable candidate being developed with Alar Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-INDV
$47.04
34.9% Upside
Undervalued
$49
40.5% Upside
Undervalued
Great
0.0%
October 29, 2026
11.6x
3.1x
4.116 B
4.403 B
11.0%
98.1%
3.8
-31.2%
Valuation • Fair Value

Indivior PLC (NASDAQ-INDV) Fair Value by Valuation Model

Review the available estimates for Indivior PLC (NASDAQ-INDV), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$47.04

Estimated upside of 34.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$62.87

Discounted cash flow valuation reference.

Ben Graham Formula Value

$33.47

Classic Ben Graham valuation formula reference.

EPV Fair Value

$31.51

Earnings power value estimate.

Comps Fair Value

$36.44

Comparable-company valuation reference.

Analyst Price Target

$49

Analysts imply upside of 40.5%.

How to read these valuation models

Use the 7 available valuation references for Indivior PLC (NASDAQ-INDV) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Indivior PLC (NASDAQ-INDV)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.331 B

Current operating scale indicator.

Revenue Forecast

1.336 B

Forward revenue estimate.

EBITDA

576 M

Current operating profitability reference.

EBITDA Forecast

728.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Indivior PLC (NASDAQ-INDV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Indivior PLC (NASDAQ-INDV)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-0.78

Higher caution zone on this screen.

Altman Z-Score

3.8

Relatively strong balance-sheet zone.

FCF / Net Income

-31.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Indivior PLC (NASDAQ-INDV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Indivior PLC (NASDAQ-INDV)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 29, 2026

Days to Earnings

41

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Indivior PLC (NASDAQ-INDV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Indivior PLC (NASDAQ-INDV) Stock Forecast & Technical Outlook

Review Indivior PLC (NASDAQ-INDV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Indivior PLC (NASDAQ-INDV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Indivior PLC (NASDAQ-INDV) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Indivior PLC (NASDAQ-INDV) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Indivior PLC (NASDAQ-INDV) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Indivior PLC (NASDAQ-INDV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Indivior PLC (NASDAQ-INDV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Indivior PLC (NASDAQ-INDV) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Indivior PLC (NASDAQ-INDV) Stock FAQ

Data-supported answers about Indivior PLC (NASDAQ-INDV), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$47.04
Estimated upside 34.9%
Valuation Rating
Undervalued
Estimated upside of 34.9%
Analyst Target
$49
Implied upside 40.5%
Financial Health
Great
Current financial-health read

The current fair value estimate for Indivior PLC (NASDAQ-INDV) is $47.04. This implies an estimated upside of 34.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 34.9% versus the current market price.

The available analyst price target for Indivior PLC (NASDAQ-INDV) is $49. The analyst target implies estimated upside of 40.5%.

The current financial health read for Indivior PLC (NASDAQ-INDV) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Indivior PLC (NASDAQ-INDV) is October 29, 2026.

The latest available data indicates no current dividend yield for Indivior PLC (NASDAQ-INDV).

The current P/E ratio listed for Indivior PLC (NASDAQ-INDV) is 11.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Indivior PLC is 4.116 B.

The current enterprise value listed for Indivior PLC is 4.403 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Indivior PLC is NASDAQ-INDV, and the stock is listed on NASDAQ.

Indivior PLC (NASDAQ-INDV) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Indivior PLC is 11.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Indivior PLC is 98.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B